|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
|
RedHill Biopharma Ltd. (Name of Issuer) |
Ordinary Shares, par value 0.001 NIS per share (Title of Class of Securities) |
757468202 (CUSIP Number) |
Anthony Varbero 233 Broadway, Suite 2120, New York, NY, 10279 2122264026 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
03/22/2024 (Date of Event Which Requires Filing of This Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
SCHEDULE 13D
|
| CUSIP No. | 757468202 |
| 1 |
Name of reporting person
Quintairos, Prieto, Wood & Boyer P.A. | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
OO | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
UNITED STATES
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
0.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
0.0 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
OO |
Comment for Type of Reporting Person:
Quintairos, Prieto, Wood & Boyer P.A. submitting 13D on behalf of Avi Polischuk, Regina Polischuk, and R&S United Services
SCHEDULE 13D
|
| Item 1. | Security and Issuer |
| (a) | Title of Class of Securities:
Ordinary Shares, par value 0.001 NIS per share |
| (b) | Name of Issuer:
RedHill Biopharma Ltd. |
| (c) | Address of Issuer's Principal Executive Offices:
21 HA'ARBA'A STREET, TEL AVIV,
ISRAEL
, 64739. |
| Item 2. | Identity and Background |
| (a) | Avi Polischu, Regina Polischuk, and R&S United Services |
| (b) | 15 Ranick Drive West Amityville Ny 11701 |
| (c) | Avi Polischuk- President |
| (d) | N/A |
| (e) | N/A |
| (f) | USA |
| Item 3. | Source and Amount of Funds or Other Consideration |
PF | |
| Item 4. | Purpose of Transaction |
IN | |
| Item 5. | Interest in Securities of the Issuer |
| (a) | 15.12% |
| (b) | Avi Polischuk- 1,325,000
Regina Polischuk- 160,000
R&S United Services- 1,875,590 |
| (c) | N/A |
| (d) | Avi Polischuk- 1,325,000
Regina Polischuk- 160,000
R&S United Services- 1,875,590 |
| (e) | March 22nd, 2024 |
| Item 6. | Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer |
N/A | |
| Item 7. | Material to be Filed as Exhibits. |
N/A |
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
Comments accompanying signature:
Anthony Varbero on behalf of Avi Polischuk |